Statistics on people receiving care in specialised drug treatment centres in 2022
The report confirms trends already observed in previous years, including persistently low referral rates from primary care, alcohol use remaining the most common reason for consultation, and clear demographic disparities depending on the substance used.
- In 2022, 270 specialised drug treatment centres (CSAPAs) out of 500 took part in the RECAP survey (Common Data Collection on Addictions and Care), enabling the analysis of the characteristics of over 179 000 patients, 49% of whom were seen for the first time in a CSAPA in 2022.
- Three patients in four were male and the average age was 41.2 years. More than half were in employment (54%).
- Patient care is mostly initiated by the patient themselves (47%), while 19% attended a CSAPA following a judicial referral order. Only 8% of patients were referred to a CSAPA through primary care.
- Patients receiving care for their cannabis use were significantly younger (29.4 years) than the overall outpatient admissions and were most often referred to CSAPAs by the justice system (41%).
- Alcohol use remained the main reason for care and affected nearly half of patients seen in 2022.
- The second most common reason for care related to the use of an illicit substance other than cannabis (mainly heroin and cocaine), accounting for 22% of patients in 2022.
- 17% of patients attended a CSAPA for cannabis use, 6% for tobacco use and 5% for a behavioural addiction (gambling, cyberaddiction, eating disorders, etc.).
- New patients were more likely to be living in insecure housing (temporary accommodation or homeless) (16%) than patients receiving ongoing care (14%).
- The proportions of injecting drug users (IDUs) among patients treated for heroin or cocaine use were lower among new patients (17% and 7% respectively) than among those in ongoing care (22% and 13% respectively).
Publication type
Briefing papers
Publication date
Language
French
English
Author(s)
VERON
Sophie
Edited by
OFDT
Number of pages
20
ISBN
979-10-92728-97-2
Products & addictions
Alcohol
Benzodiazepines and gabapentinoids
Cannabis
Cocaine and crack
GHB and solvents
Hallucinogènes
Heroin and opioids
Gambling
Ketamine
LSD and mushrooms
MDMA/ecstasy and amphetamine
New Psychoactive Substances
Tobacco
Others
Themes
Treatment
Specific population(s)
Adults
Women/Men
Vulnerable groups
Territories
France
Dispositif d'enquête et d'observation
Medico-administrative analysis